Ahmedabad: Torrent Pharma has announced the appointment of Aman Mehta, third generation of Torrent Group’s founder Mehta family, as Managing Director and Whole-time Key Managerial Personnel of the Company for the period of 5 years w.e.f. 1st August, 2025.He is son of Samir Mehta, the current chairman of Torrent Pharma. He was appointed to the post of Whole-time Director at the company in August 2022.”We would like to inform that the Board has at its meeting held recommended appointment of Aman Mehta (holding DIN: 08174906), who is currently the Whole-time Director of the Company, as Managing Director and Whole-time Key Managerial Personnel of the Company for the period of 5 years w.e.f. 1st August, 2025 by pre-closing his current appointment as “Whole-time Director” subject to approval of shareholders of the Company at the ensuing Annual General Meeting,” Torrent stated in a BSE filing.Aman Mehta holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York. He brings with him a dynamic blend of academic excellence and practical leadership experience across diverse business sectors.
During his 10+ year tenure with Torrent, Aman has held key leadership positions in both the Power and Pharma verticals of the Group. As an Executive Director at Pharma, Aman has primarily been involved in the India business, Torrent’s largest revenue contributor. He played an instrumental role in the seamless integration of the Unichem acquisition and the strategic identification and integration of Curatio Healthcare, both of which delivered substantial value and synergies to the Company. The Torrent Group, founded by Late Mr. U. N. Mehta in 1959.Read also: Torrent Pharmaceutical gets CDSCO Panel nod to conduct bioequivalence study of Prucalopride oral solutionTorrent Pharmaceuticals, headquartered in Ahmedabad, Gujarat, is a prominent Indian pharmaceutical company known for developing, manufacturing, and marketing branded and generic medications. It operates across various therapeutic areas, including cardiovascular, central nervous system, and diabetes care, with a strong presence in both regulated and emerging global markets.